Literature DB >> 20435650

Discrepancies in categorizing rheumatoid arthritis patients by DAS-28(ESR) and DAS-28(CRP): can they be reduced?

Elizabeth M A Hensor1, Paul Emery, Sarah J Bingham, Philip G Conaghan.   

Abstract

OBJECTIVES: The 28-joint disease activity score (DAS-28) guides the use of biologics in RA. The aims of this study were to investigate agreement between the ESR- and CRP-based DAS-28 definitions, and to examine how this agreement may be improved.
METHODS: Data were obtained from registers of early (n = 520) and established RA (n = 364) patients. Agreement over disease activity levels (remission, low, moderate and high) at baseline and 6 months, and EULAR responder status at 6 months, were assessed in the early cohort. Two alternative DAS-28(CRP) definitions, obtained through linear regression analyses at baseline in the early RA patients, were validated with 6-month data from both the cohorts.
RESULTS: In early RA patients, despite a high percentage of exact agreement over DAS-28 categories (88.2%), 38 (30.4%) of 125 patients with 'moderate' DAS-28(CRP) at baseline had 'high' DAS-28(ESR). This agreement was improved by modifying the DAS-28(CRP) definition, and by incorporating age and gender: e.g. in early RA patients with moderate original DAS-28(CRP), 30.4% had 'high' DAS-28(ESR), whereas 3.2% had 'low' DAS-28(ESR); following DAS-28(CRP) transformation both proportions were 6.6%. Incorporating age and gender did not improve agreement over EULAR response states.
CONCLUSION: The DAS-28(ESR) and DAS-28(CRP) definitions differ substantially in classifying RA patients as having moderate or high disease activity, with the ESR definition resulting in a higher proportion of high DAS-28 especially in women. Our results suggest that modifying the DAS-28(CRP) definition may improve agreement with DAS-28(ESR). There are important implications for meta-analyses and for therapy driven by DAS scores.

Entities:  

Mesh:

Year:  2010        PMID: 20435650     DOI: 10.1093/rheumatology/keq117

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  21 in total

1.  Is DAS28-CRP with three and four variables interchangeable in individual patients selected for biological treatment in daily clinical practice?

Authors:  Ole Rintek Madsen
Journal:  Clin Rheumatol       Date:  2011-09-29       Impact factor: 2.980

2.  Interchangeability of 28-joint disease activity scores using the erythrocyte sedimentation rate or the C-reactive protein as inflammatory marker.

Authors:  Liseth Siemons; Harald E Vonkeman; Peter M ten Klooster; Piet L C M van Riel; Mart A F J van de Laar
Journal:  Clin Rheumatol       Date:  2014-02-23       Impact factor: 2.980

Review 3.  [Choosing wisely recommendations in rheumatology : One year after their first publication].

Authors:  E Märker-Hermann; A J Voormann
Journal:  Internist (Berl)       Date:  2017-06       Impact factor: 0.743

4.  [How frequent are poor prognostic markers in rheumatoid arthritis? : An estimate based on three epidemiologic cohorts].

Authors:  K Albrecht; A Richter; Y Meissner; D Huscher; L Baganz; K Thiele; M Schneider; A Strangfeld; A Zink
Journal:  Z Rheumatol       Date:  2017-06       Impact factor: 1.372

Review 5.  Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.

Authors:  Jaclyn Anderson; Liron Caplan; Jinoos Yazdany; Mark L Robbins; Tuhina Neogi; Kaleb Michaud; Kenneth G Saag; James R O'Dell; Salahuddin Kazi
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

Review 6.  [Differentiated laboratory diagnostics of rheumatic diseases].

Authors:  C Specker
Journal:  Orthopade       Date:  2018-11       Impact factor: 1.087

7.  Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis.

Authors:  Ashutosh Tamhane; David T Redden; Gerald McGwin; Elizabeth E Brown; Andrew O Westfall; Richard J Reynolds; Laura B Hughes; Doyt L Conn; Leigh F Callahan; Beth L Jonas; Edwin A Smith; Richard D Brasington; Larry W Moreland; S Louis Bridges
Journal:  J Rheumatol       Date:  2013-08-15       Impact factor: 4.666

8.  Validity and Agreement between the 28-Joint Disease Activity Score Based on C-Reactive Protein and Erythrocyte Sedimentation Rate in Patients with Rheumatoid Arthritis.

Authors:  Louise Nielung; Robin Christensen; Bente Danneskiold-Samsøe; Henning Bliddal; Christian Cato Holm; Karen Ellegaard; Hanne Slott Jensen; Else Marie Bartels
Journal:  Arthritis       Date:  2015-01-14

9.  Blood monocyte chemotactic protein-1 (MCP-1) and adapted disease activity Score28-MCP-1: favorable indicators for rheumatoid arthritis activity.

Authors:  Lieh-bang Liou; Wen-pin Tsai; Chee J Chang; Wan-ju Chao; Meng-hsin Chen
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

10.  Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker.

Authors:  Yong Gil Hwang; Goundappa K Balasubramani; Ilinca D Metes; Marc C Levesque; S Louis Bridges; Larry W Moreland
Journal:  Arthritis Res Ther       Date:  2016-05-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.